chevron_leftBack
As of 13 June 2026, SIGA Technologies, Inc. has a market cap of $324.55M USD, ranking #18094 globally and #3012 in the United States.
It ranks #1642 in the Healthcare sector, and #593 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$324.55MUSD
Enterprise Value
$168.91MUSD
Revenue (TTM)
$94.57MUSD
EBITDA (TTM)
$24.26MUSD
Net Income (TTM)
$23.28MUSD
EBITDA Margin
26%
Profit Margin
25%
PE Ratio
14.2
Forward PE
50.3
PS Ratio
3.4
PB Ratio
1.7
EV/EBITDA
7.0
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Diem Nguyen
open_in_new
Employees
49
Founded
1995
IPO
09 Sep 1997
Website
siga.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -1.3% | 0.4% | -15% | -32% | -46% | -29% |
News
Loading...
SIGA Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
SIGA
SIGA Technologies Inc
ISIN: US8269171067
Shares Out.:
Shares Outstanding:
71.724M1
Shares Float:
41.124M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
4.53 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About SIGA Technologies, Inc.
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. The company’s lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. was incorporated in 1995 and is headquartered in New York, New York.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
235K%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
169K%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
111K%
|
97.4
|
|
NYSE: MRK
|
$274.03B
84K%
|
15.1
|
|
NYSE: PFE
|
$149.38B
46K%
|
19.5
|
|
NYSE: BMY
|
$117.58B
36K%
|
16.8
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
SIX: RO
|
$321.52B
99K%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$288.84B
89K%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$274.65B
85K%
218.9B CHF
|
20.5
|
|
CPH: NOVO-B
|
$181.82B
56K%
1.18T DKK
|
11.5
|
|
EPA: SAN
|
$110.1B
34K%
95.26B EUR
|
19.9
|
|
LSE: GSK
|
$108.46B
33K%
80.96B GBP
|
14.6
|
chevron_leftBack